Knowledge Center

Ash Stevens CEO to Chair Session on Cancer Drug Development at American Association for Cancer Research Annual Meeting

Detroit—April 10, 2008—Ash Stevens Inc.TM (ASI) President and CEO Dr. Stephen Munk will chair an educational session for the Chemistry in Cancer Research Working Group (CICR) at the American Association for Cancer Research (AACR) annual meeting on Saturday, April 12 at the San Diego Convention Center.

Dr. Munk's session will highlight the unique developmental challenges of safely manufacturing highly potent active pharmaceutical ingredients (APIs) used in cancer drugs. Speakers from Genzyme Corporation, SRI International, Infinity Pharmaceuticals, and Abbott Laboratories will participate in the session, titled "From Chemistry to the Clinic: Pathways for Drug Discovery and Development Part 4: Chemical Development: Translating a Potent Agent into a Registered Product."

About Ash Stevens, Inc.
Ash Stevens, Inc. (ASI) is a full service Contract Pharmaceutical Manufacturer offering comprehensive small-molecule drug substance development and cGMP manufacturing services. Founded in 1962 and headquartered in Detroit, Michigan, ASI has extensive experience developing and manufacturing Active Pharmaceutical Ingredients (APIs) for commercial clients in the Life Sciences industry developing innovator small-molecule drugs. ASI is also a longtime provider of contract research services to the National Institutes of Health and the National Cancer Institute and has worked on many of the drugs developed through these government agencies. To date, ASI has received eleven FDA manufacturing approvals for innovator APIs, including Four Fast-Track manufacturing approvals for the active ingredients in the oncology drugs Velcade®, Vidaza®, and Clolar®. Services offered by Ash Stevens include: process development and scale-up; cGMP manufacturing; the development and cGMP manufacture of highly potent APIs using barrier-isolation technology; comprehensive analytical capabilities (including method development, stability studies and qualification of reference standards); and regulatory support for all phases of drug development and manufacturing. For more information, visit